BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Hemophilia Alliance - ECPv6.3.7//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://hemoalliance.org
X-WR-CALDESC:Events for Hemophilia Alliance
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20260308T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20261101T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260312T130000
DTEND;TZID=America/New_York:20260312T140000
DTSTAMP:20260422T205531
CREATED:20260302T162852Z
LAST-MODIFIED:20260302T162852Z
UID:72482-1773320400-1773324000@hemoalliance.org
SUMMARY:🟥 Member Webinar : Hemophilia Alliance Hosts - A Webinar from Takeda - Inhibitor Development in Hemophilia A: A Continuing Clinical Challenge Despite Therapeutic Advances
DESCRIPTION:Date: Thursday\, March 12th\, 2026\nTime: 1:00pm – 2:00pm ET \n \n  \n  \n  \n \n  \nWEBINAR TOPIC: \nInhibitor Development in Hemophilia A: A Continuing Clinical Challenge Despite Therapeutic Advances. \nOBJECTIVE: \nAfter this webinar\, participants will be able to: \n\nDescribe the clinical impact and risk factors for FVIII inhibitor development in Previously Untreated Patients (PUPs)\nSummarize key findings from past PUP studies\, including the SIPPET trial\nReview Phase 3 PUP trial data for rurioctocog alfa pegol\nDiscuss implications for monitoring and managing inhibitor risk in current clinical practice\n\nAUDIENCE: \nAll HTC Staff. \nSPEAKERS: \n \nCaitlin Montcrieff\, MSN\, CPNP – Director\, US Medical Hematology & Rare Disease \n  \n  \n  \n  \n \nRobert Sidonio\, MD\, MSc \nDr. Robert F. Sidonio\, Jr\, MD\, MSc is a Professor of pediatrics at Emory University School of Medicine and the Medical Director of the Hemophilia of Georgia Pediatric Center for Bleeding and Clotting Disorders of Emory. Dr. Sidonio’s clinical and research interests are in the management of pediatric patients with bleeding disorders. His research focus has included women with bleeding disorders\, von willebrand disease and the study of inhibitor development in patients with Hemophilia A. Dr. Sidonio was the principal investigator for the Phase 3 clinial trial of rurioctocog alfa pegol in previously untreated patients with Hemophilia A.
URL:https://hemoalliance.org/alliance-events/a-webinar-from-takeda-inhibitor-development-in-hemophilia-a-a-continuing-clinical-challenge-despite-therapeutic-advances/
CATEGORIES:Members Only
END:VEVENT
END:VCALENDAR